SANOFI : and Aviesan Renew their Agreement to Accelerate Research in France

COMMUNIQUE DE PRESSE

- Three-year renewal of the cooperation protocol -

Paris, France - September 27, 2013 - Sanofi (EURONEXT: SAN and NYSE: SNY) and Aviesan1, the French National Alliance for Life Sciences and Health today announced that they have renewed for a period of three years the cooperation protocol signed in 2010.The aim is to contribute to the development of new treatments that target unmet medical needs, including those in the field of rare diseases, to participate to the excellence and consolidation of research in French industry on an international level. Special emphasis will be put on translational research projects that bring together clinical and medical teams with fundamental research teams to translate research successes into medical advances.

"As well as strengthening existing ties, this new agreement will allow us to explore other avenues of research," said Professor André Syrota, President of Aviesan. "Translational research combines clinical and basic research, underscoring the critical importance of linking industrial and academic expertise."

Several projects under this new protocol are under discussion, including the creation of centers of excellence as part of future investments, particularly in collaboration with IHUs (University Hospital Institutes) and IRTs (Technological Research Institutes).

"With the signing of several projects between Sanofi and Aviesan during the past three years, Sanofi has become the leading private partner of academic research in the life sciences," said Dr Elias Zerhouni, President, Global Research & Development, Sanofi. "Strategic and operational committees have worked tirelessly to achieve this convergence of the best in French academic excellence and our own teams. We all committed to pursuing these vital interactions in order to accelerate scientific discoveries for the benefit of patients."

The new cooperation between Aviesan and Sanofi research teams will also spur the development of technology platforms to finance the work of researchers (e.g. the ATIP-Avenirs program), CIFRE fellows, post-docs, and staff secondment.
A Strategy Committee and an Operational Steering Committee, each consisting of eight directors divided equally between Aviesan and Sanofi, will coordinate interactions between the different players, as well as preparing and validating projects and monitoring their implementation.

1 An alliance between CEA, the CNRS, INRA, INRIA, Inserm, the Institut Pasteur, the IRD, the Conference of University

Presidents and the Conference of Managing Directors of regional and university hospitals.

1/3

The cooperation protocol signed in 2010 between Sanofi and Aviesan is based on three pillars. First, collaboration agreements with Aviesan research teams. Second, the creation of teams of young researchers supported by additional funding from the ATIP-Avenirs program, a joint CNRS and INSERM initiative. Third, Sanofi is a member of the COPIO (interagency Steering Committee) tasked with setting up and bringing to maturity inter-agency projects that help with medical progress and the development of the healthcare industry, through which Sanofi has funded several projects.
In three years, Sanofi has signed 15 collaborative projects with Aviesan's French teams of academic excellence, as well as providing additional funding to 16 young scientists who won ATIP-Avenirs grants and investing in four COPIO projects. Over 10 million euros were invested by Sanofi in 2012 for these collaborations.

France's National Alliance for Life Sciences and Health (Aviesan) encompasses the CEA, CNRS, INRA, INRIA, INSERM, Institut Pasteur, IRD, the CPU and the Conference of Managing Directors of regional and university hospitals, as well as 10 associate members: Ariis, CIRAD, EFS, Fondation Mérieux, Ineris, the Curie Institute, IRSN, IRBA, Institut Mines-Telecom and Unicancer. Aviesan aims to develop a seamless continuum from basic research to practical applications at the very highest level in all areas of life sciences and healthcare research. The National Alliance for Life Sciences and Health is organized into 10 multi-organization thematic institutes that coordinate the research and are tasked with providing an audit of French research on the basis of major themes. www.aviesan.fr

Sanofi, an integrated global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to

future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject

to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward- looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such

as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit

from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2012. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information

or statements, notably Articles 223-1 et seq. of the general regulations of the AMF.

2/3

Laurence Bollack Priscille Rivière
Tel: 01 53 77 46 46 Tel: 01 44 23 60 97 mr@sanofi.com presse@inserm.fr

3/3

distributed by